Spherix Global Insights’ recently released survey of 103 US gastroenterologists reveals that practitioners project significant growth in the use vedolizumab, golimumab, and Pfizer’s Inflectra, an infliximab biosimilar, for the treatment of ulcerative colitis over the next 6 months.
Spherix Global Insights’ recently released survey of 103 US gastroenterologists reveals that practitioners project significant growth in the use vedolizumab (Entyvio), golimumab (Simponi), and Pfizer’s Inflectra (an infliximab biosimilar of Janssen’s reference drug Remicade), for the treatment of ulcerative colitis (UC) over the next 6 months.
The study suggests that, while the positive increases in Entyvio’s and Simponi’s shares of the UC market will be driven largely by increased prescriptions for current users, projected growth in the use of Inflectra is primarily driven by increases to the user base, which is anticipated to more than double over the next 6 months.
Vedolizumab, licensed to Takeda, is an intravenously infused monoclonal antibody that is indicated for use in adult patients who have moderate to severe UC or Crohn’s disease (CD). Golimumab, Janssen’s tumor necrosis factor blocker, is a subcutaneous injection indicated for use in patients who have moderate to severe rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and moderately to severely active UC. Inflectra (infliximab-dyyb) for injection, the second FDA-approved biosimilar, is approved for the treatment of UC, CD, pediatric CD, RA, AS, PsA, and plaque psoriasis.
The gastroenterologists surveyed were recruited for an online survey from the Spherix Network. This group of clinical gastroenterologists agree to be revisited periodically in order to share insights into strategically important issues in the gastroenterology field, including the ongoing trajectory of Entyvio, the prominence of off-label prescribing in patients with UC, key barriers across brands, and the evolution of the inflammatory bowel disease (IBD) pipeline.
The Spherix study concludes that, despite unexpected growth in the use of the infliximab biosimilar Inflectra, the current leading barrier to its adoption is the lack of insurance mandates for its use. “Only 14% of respondents report ever being contacted by a pharmacy or insurance company regarding use of Inflectra instead of Janssen’s Remicade,” the report states. Among the few gastroenterologists who have been contacted, most made no changes to the treatment plan and continued to prescribe Remicade. Remicade continues to lead the UC biologics market, yet it is expected that payers will soon increase pressure to prescribe Inflectra, helping to fuel the biosimilar’s future gains.
Off-label use of products being studied for IBD but approved for other autoimmune conditions is an additional factor potentially impacting the UC market, according to the report. Half of the survey respondents said that they would be more comfortable prescribing a newly approved drug in IBD that already has significant post-marketing experience in another indication than prescribing a drug with a completely novel mechanism of action.
When questioned about familiarity with agents in the research pipeline, gastroenterologists reported the greatest familiarity with Pfizer’s Xeljanz (tofacitinib citrate, an oral RA treatment). Their familiarity with this drug was significantly greater than their familiarity with Celgene’s investigational drugs, mongersen (for CD) and ozanimod (for CD and MS), or with Roche and Genentech’s investigational UC and CD treatment, etrolizumab.
“The key to getting market entrants in the UC space will not only be getting patients on these new therapies but augmenting current persistency rates, as the study revealed that over half of the patients spent no more than 6 months on their prior biologic brand before being switched,” the report shows. “Opportunity to improve UC outcomes abounds, as the participating gastroenterologists report that only 58% of their biologic-treated UC patients are well-managed on their current agent.”
Spherix Global Insights’ independent reports are designed and developed by Spherix, a business intelligence and market research company specializing in renal, autoimmune, neurologic, and rare disease. The latest quarterly update on UC was released in July 7, 2017.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.